Gillian Gresham1, Jennifer Schrack2, Louise M Gresham3, Arvind M Shinde4, Andrew E Hendifar4, Richard Tuli4, B J Rimel4, Robert Figlin4, Curtis L Meinert2, Steven Piantadosi4. 1. Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, United States; Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, United States. Electronic address: ggresha3@jhu.edu. 2. Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, United States. 3. University of Ottawa, Department of Medicine, Canada. 4. Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, United States.
Abstract
BACKGROUND: Physical activity is an important outcome in oncology trials. Physical activity is commonly assessed using self-reported questionnaires, which are limited by recall and response biases. Recent advancements in wearable technology have provided oncologists with new opportunities to obtain real-time, objective physical activity data. The purpose of this review was to describe current uses of wearable activity monitors in oncology trials. METHODS: We searched Pubmed, Embase, and the Cochrane Central Register of Controlled Trials for oncology trials involving wearable activity monitors published between 2005 and 2016. We extracted details on study design, types of activity monitors used, and purpose for their use. We summarized activity monitor metrics including step counts, sleep and sedentary time, and time spent in moderate-to-vigorous activity. RESULTS: We identified 41 trials of which 26 (63%) involved cancer survivors (post-treatment) and 15 trials (37%) involved patients with active cancer. Most trials (65%) involved breast cancer patients. Wearable activity monitors were commonly used in exercise (54%) or behavioral (29%) trials. Cancer survivors take between 4660 and 11,000 steps/day and those undergoing treatment take 2885 to 8300steps/day. CONCLUSION: Wearable activity monitors are increasingly being used to obtain objective measures of physical activity in oncology trials. There is potential for their use to expand to evaluate and predict clinical outcomes such as survival, quality of life, and treatment tolerance in future studies. Currently, there remains a lack of standardization in the types of monitors being used and how their data are being collected, analyzed, and interpreted. PRECIS: Recent advancements in wearable activity monitor technology have provided oncologists with new opportunities to monitor their patients' daily activity in real-world settings. The integration of wearable activity monitors into cancer care will help increase our understanding of the associations between physical activity and the prevention and management of the disease, in addition to other important cancer outcomes.
BACKGROUND: Physical activity is an important outcome in oncology trials. Physical activity is commonly assessed using self-reported questionnaires, which are limited by recall and response biases. Recent advancements in wearable technology have provided oncologists with new opportunities to obtain real-time, objective physical activity data. The purpose of this review was to describe current uses of wearable activity monitors in oncology trials. METHODS: We searched Pubmed, Embase, and the Cochrane Central Register of Controlled Trials for oncology trials involving wearable activity monitors published between 2005 and 2016. We extracted details on study design, types of activity monitors used, and purpose for their use. We summarized activity monitor metrics including step counts, sleep and sedentary time, and time spent in moderate-to-vigorous activity. RESULTS: We identified 41 trials of which 26 (63%) involved cancer survivors (post-treatment) and 15 trials (37%) involved patients with active cancer. Most trials (65%) involved breast cancerpatients. Wearable activity monitors were commonly used in exercise (54%) or behavioral (29%) trials. Cancer survivors take between 4660 and 11,000 steps/day and those undergoing treatment take 2885 to 8300steps/day. CONCLUSION: Wearable activity monitors are increasingly being used to obtain objective measures of physical activity in oncology trials. There is potential for their use to expand to evaluate and predict clinical outcomes such as survival, quality of life, and treatment tolerance in future studies. Currently, there remains a lack of standardization in the types of monitors being used and how their data are being collected, analyzed, and interpreted. PRECIS: Recent advancements in wearable activity monitor technology have provided oncologists with new opportunities to monitor their patients' daily activity in real-world settings. The integration of wearable activity monitors into cancer care will help increase our understanding of the associations between physical activity and the prevention and management of the disease, in addition to other important cancer outcomes.
Authors: Marta Karas; Jiawei Bai; Marcin Strączkiewicz; Jaroslaw Harezlak; Nancy W Glynn; Tamara Harris; Vadim Zipunnikov; Ciprian Crainiceanu; Jacek K Urbanek Journal: Stat Biosci Date: 2019-01-12
Authors: Siobhan M Phillips; Linda M Collins; Frank J Penedo; Kerry S Courneya; Whitney Welch; Alison Cottrell; Gillian R Lloyd; Kara Gavin; David Cella; Ronald T Ackermann; Juned Siddique; Bonnie Spring Journal: Contemp Clin Trials Date: 2018-01-09 Impact factor: 2.226
Authors: Caroline Himbert; Nicole Klossner; Adriana M Coletta; Christopher A Barnes; Joachim Wiskemann; Paul C LaStayo; Thomas K Varghese; Cornelia M Ulrich Journal: Crit Rev Oncol Hematol Date: 2020-09-13 Impact factor: 6.312
Authors: Linda F Wang; Yvonne L Eaglehouse; Janette T Poppenberg; Jill W Brufsky; Emily M Geramita; Shuyan Zhai; Kelliann K Davis; Bethany Barone Gibbs; Jason Metz; G J van Londen Journal: Breast Cancer Date: 2021-03-10 Impact factor: 4.239
Authors: Ellora Sen-Gupta; Donald E Wright; James W Caccese; John A Wright; Elise Jortberg; Viprali Bhatkar; Melissa Ceruolo; Roozbeh Ghaffari; Dennis L Clason; James P Maynard; Arthur H Combs Journal: Digit Biomark Date: 2019-03-01
Authors: Ross D Dolan; Louise E Daly; Claribel Pl Simmons; Aoife M Ryan; Wei Mj Sim; Marie Fallon; Derek G Power; Andrew Wilcock; Matthew Maddocks; Michael I Bennett; Caroline Usborne; Barry J Laird; Donald C McMillan Journal: Cancers (Basel) Date: 2020-05-08 Impact factor: 6.639